Evidence map›Paper›PMID 38745750›Full record

ArticleMolecular therapy. Oncology2024

Targeted treatment of chondrosarcoma with a bacteriophage-based particle delivering a secreted tumor necrosis factor-related apoptosis-inducing ligand.

Aitthiphon Chongchai, Kaoutar Bentayebi, Grace Chu, Wenqing Yan, Sajee Waramit, Thanyaluck Phitak, Prachya Kongtawelert, Peraphan Pothacharoen, Keittisak Suwan, Amin Hajitou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Recent Advances and Mechanisms of Phage-Based Therapies in Cancer Treatment.International journal of molecular sciences · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aitthiphon ChongchaiCancer Phage Therapy Laboratory, Department of Brain Sciences, Imperial College London, W12 0NN London, UK.
Kaoutar BentayebiCancer Phage Therapy Laboratory, Department of Brain Sciences, Imperial College London, W12 0NN London, UK.
Grace ChuCancer Phage Therapy Laboratory, Department of Brain Sciences, Imperial College London, W12 0NN London, UK.
Wenqing YanCancer Phage Therapy Laboratory, Department of Brain Sciences, Imperial College London, W12 0NN London, UK.
Sajee WaramitCancer Phage Therapy Laboratory, Department of Brain Sciences, Imperial College London, W12 0NN London, UK.
Thanyaluck PhitakThailand Excellence Centre for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Prachya KongtawelertThailand Excellence Centre for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Peraphan PothacharoenThailand Excellence Centre for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Keittisak SuwanCancer Phage Therapy Laboratory, Department of Brain Sciences, Imperial College London, W12 0NN London, UK.
Amin HajitouCancer Phage Therapy Laboratory, Department of Brain Sciences, Imperial College London, W12 0NN London, UK.

Funding

Cancer Research UK 25887Medical Research Council MR/T029226/1
6 · The paper itself

Abstract

Chondrosarcoma (CS) is a malignant cartilage-forming bone tumor that is inherently resistant to chemotherapy and radiotherapy, leaving surgery as the only treatment option. We have designed a tumor-targeted bacteriophage (phage)-derived particle (PDP), for targeted systemic delivery of cytokine-encoding transgenes to solid tumors. Phage has no intrinsic tropism for mammalian cells; therefore, it was engineered to display a double cyclic RGD4C ligand on the capsid to target tumors. To induce cancer cell death, we constructed a transgene cassette expressing a secreted form of the cytokine tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL). We detected high expression of αvβ3 and αvβ5 integrin receptors of the RGD4C ligand, and of the TRAIL receptor-2 in human CS cells (SW1353), but not in primary normal chondrocytes. The RGD4C.PDP-

Indexed as

bacteriophagecancer treatmentchondrosarcomagene therapyMT: Regular Issuesystemic deliverytargeted cytokine therapytargeted gene deliveryTRAILtumor targeting

Identifiers

PMID38745750
PMCPMC11090904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.